QuintilesIMS Delivers Integrated Information and Technology Solutions to Drive Healthcare Forward
Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.
For more information please visit www.quintilesims.com.
Driving Healthcare Performance in Taiwan
Established in Taipei in 1982, QuintilesIMS Taiwan has one of the most comprehensive offering portfolios in the region, with solutions for local companies and affiliates of multinational companies in the life sciences industry including market data (sell-out, sell-in and prescription data services), primary market research, commercial effectiveness services and consulting services.
QuintilesIMS is the leading pharmaceutical market information provider with more than 100 affiliates around the world. In Taiwan, our data and research scopes cover hospital, drug store and clinic channels. As a result of continuous efforts made since 1983, QuintilesIMS local audits have become an indispensable reference tool for researchers, marketers and senior management to analyze market dynamics, forecast future trends, and monitor business effectiveness among others.
With the robust growth of the oncology business in Taiwan, we brought in Oncology Analyzer (OA) in 2008 to support our clients in getting a profound understanding of prescription behavior, prescription dynamics, treatment flows, and others.
Moving forward to 2014 and beyond, QuintilesIMS Taiwan will take a step ahead to enhance the quality of QuintilesIMS local audits and OA, as well as integrate all QuintilesIMS offerings and services to provide real solutions, and introduce new businesses such as IMS Consumer Health Analysis and Health Economics and Outcome Research (HEOR) to meet emerging client needs.
The size of the total pharmaceutical market in Taiwan reached US$4.76 billion in 2013, reflecting a decline of 5.5% in growth from the previous year. The market is expected to grow with a CAGR of 2.9% up to 2018.
Growing attention to the health promotion and disease prevention as chronic disease are on the increase due to aging population, coupled with improvement in the National Health Insurance (NHI) financial situation following the implementation of the 2G NHI Act in 2013, are expected to drive growth.
Challenges remain due to the low prices awarded to new drugs, and the downwards trend caused by the biennial price-volume survey (PVS) cuts. If pharmaceutical sales growth exceeds the set target following implementation of a DET global budget system, further price cuts are expected. This, together with price cuts for products losing patent protection and the requirement of price reductions to a 'reasonable' level within five years, is also a concern for multinationals.
In today's highly competitive and complex environment, contact your QuintilesIMS Taiwan representative to gain greater clarity and stay one step ahead of the competition with the valuable insights gained from QuintilesIMS offerings.